Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
March 10, 2026
The scheduling of novel synthetic opioids such as butonitazene, flunitazene, and metodesnitazene in Schedule I highlights their high abuse potential. This regulatory update aids clinicians in recognizing these substances with no accepted medical use.…
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
March 10, 2026
The schedules of controlled substances placement by the DEA now include etodesnitazene, N-pyrrolidino etonitazene, and protonitazene in Schedule I. These synthetic opioid analogs have high abuse potential and no accepted medical use. Clinicians should be…